Bapineuzumab,P3 clinical trials now the leader in the race for alzimers treatment Dr. Daniel Chain, is the inventor and patent holder for the technology platform on which most of the leading drug candidates (most visibily Bapineuzumab) http://biomedreports.com/articles/most-popular/51039-exclusive-numerous-false-starts-by-others-dont-discourage-this-companys-search-for-alzheimers-treatment.html Narration: Alzheimer's affects over 30 million people worldwide. That number is expected to double in the next 30 years. "Early-onset" Alzheimer's can affect people as young as 40. Dr. Chain: We believe that the root cause for Alzheimer's disease is the accumulation of a protein known as beta-amyloid in the brain of Alzheimer's patients. http://www.alzheimersweekly.com/Research/how-vaccines-clear-alzheimers-plaque-a800.html
Market Data 
Markets
AI
